Importantly, the rate of grade 3/4 events (infections, neutropenia, anemia, thrombocytopenia) of our alternate-day pomalidomide schedule appeared numerically almost 50% lower than that reported for trials using standard dosing, despite the lack of G-CSF prophylaxis and a higher proportion of patients aged >75 years. The gene discussed is CSF3; the disease is neutropenia.